Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

SEATTLE, Nov. 12 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced today financial results for its third quarter and nine months ended Sept. 30, 2007.

Third Quarter and Nine Months Financial Results

Revenue for the third quarter and nine months ended Sept. 30, 2007, was $4.6 million and $14.5 million, respectively, compared with $16.5 million and $30.2 million, respectively, in 2006. The three- and nine-month decreases were due to decreased milestone revenue, reduced reimbursement revenue from the Wyeth collaboration as a result of the successful transfer of manufacturing activities for TRU-015 from Trubion to Wyeth during 2007, and decreased revenue from the recognition of the $40 million up-front fee from Wyeth due to a change in the estimated research and development service period. These decreases were partially offset by an increase in reimbursable clinical costs related to Trubion's Phase IIb clinical trial for TRU-015 completed in July 2007.

Total operating expenses for the third quarter and nine months ended Sept. 30, 2007, were $11.5 million and $35.9 million, respectively, compared with $11.6 million and $30.6 million, respectively, in 2006. The three-month decrease was primarily due to a decrease in outside manufacturing costs for TRU-015 due to the successful transfer of manufacturing activities to Wyeth during 2007. This decrease was partially offset by increased clinical costs related to our Phase IIb clinical trial for TRU-015, increased personnel- related expenses due to increased headcount and increased outside manufacturing costs related to our TRU-016 product candidate.

The nine-month increase was primarily due to increased clinical costs related
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... together supply chain risk management and resiliency practitioners with luminaries and thought leaders ... practices, and be recognized for their innovations and performance excellence. At that time ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.17 billion by 2018 ... The near future will bring Biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... people with Down syndrome, news from Elixirgen, LLC ... in the Science + Technology Park at Johns Hopkins, ... for people with Down syndrome and other chromosome disorders in ... Edwards syndrome aneuploidies in human cell cultures, " published ... to develop this technology into a treatment for the ...
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... BEIJING, China , May 12 /PRNewswire-Asia-FirstCall/ ... a leading developer,manufacturer, and distributor of Shengmingsu brand plant and animal ... announced its,financial results for the quarter ended March 31, 2010 ... -- Revenue increased 100.5% to $24.9 million from the ...
... /PRNewswire-FirstCall/ - Mr. Richard Gilbertson reports: , ... IGEN has established offices in the US (212-518-6099), Canada (778-786-2922) and ... . Our website www.igen-networks.com is being constructed to reflect our growth internationally ... , , IGEN ...
... BioCrossroads, Indiana Seed Fund, Indiana ,s only targeted ... in AgeneBio, an Indianapolis -based biotechnology start-up company focused on ... memory disorders.  , , ... More than 5 million Americans suffer from Alzheimer,s disease (AD), ...
Cached Biology Technology:Yongye International Announces First Quarter 2010 Results 2Yongye International Announces First Quarter 2010 Results 3Yongye International Announces First Quarter 2010 Results 4Yongye International Announces First Quarter 2010 Results 5Yongye International Announces First Quarter 2010 Results 6Yongye International Announces First Quarter 2010 Results 7Yongye International Announces First Quarter 2010 Results 8Yongye International Announces First Quarter 2010 Results 9Yongye International Announces First Quarter 2010 Results 10Yongye International Announces First Quarter 2010 Results 11Yongye International Announces First Quarter 2010 Results 12Yongye International Announces First Quarter 2010 Results 13Yongye International Announces First Quarter 2010 Results 14Igen Networks Corp continues to build a world class advisory board 2Igen Networks Corp continues to build a world class advisory board 3Igen Networks Corp continues to build a world class advisory board 4BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 3BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 4
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... de 2015 La 10 th International Conference ... de BGI del 22 al 25 de octubre de 2015 en ... año, la conferencia celebra su décimo aniversario. Desde su inauguración ... de las reuniones anuales más influyentes del mundo en el ... dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... study to assess the social impact of food allergies ... 35 percent of children with food allergies, who are ... experienced bullying, teasing, or harassment as a result of ... or harassment, 86 percent were reported to have experienced ...
... Long before geese started flying in chevron formation or cyclists ... to reduce drag on their spores so as to spread ... fungus, the destructive Sclerotinia sclerotiorum , spews thousands of ... to nearly zero and even creates a wind that carries ...
... Rice University physicist Dmitri Lapotko has demonstrated that plasmonic ... can detect and destroy cancer cells in vivo by ... and selectively explode them. A paper in the ... details the effect of plasmonic nanobubble theranostics on zebra ...
Cached Biology News:First study of its kind finds children with food allergies are often victims of bullying 2Fungal spores travel farther by surfing their own wind 2Fungal spores travel farther by surfing their own wind 3Fungal spores travel farther by surfing their own wind 4'Gold' fish thrive, cancers die 2'Gold' fish thrive, cancers die 3
... an aqueous solution that contains a purified ... a PBS buffer (phosphate buffered saline), pH ... not contain a preservative. StabilCoat Immunoassay ... dried protein components in immunoassays and can ...
...
... sequence analysis software with the DeCypher Engine accelerator ... you can perform searches like these from your ... database in under 6 days Align ... Use HMM analysis to compare 100,000 sequences ...
... The Infinite 200 series of microplate ... or absorbance detection in an affordable, easy-to-use ... science applications. The unique modular design and ... researchers with a choice of a monochromator ...
Biology Products: